Telix Pharmaceuticals (TLX) said over the weekend it filed a biologics license application with the US Food and Drug Administration for TLX250-CDx for the diagnosis and characterization of clear cell renal cell carcinoma, a form of kidney cancer.
The regulator is expected to advise the target action date under the Prescription Drug User Fee Act for the product following a 60-day administrative review process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.